文章摘要
刘奕晨,孙志强,郑方.嵌合抗原受体T细胞免疫疗法治疗多发性骨髓瘤的研究进展[J].安徽医药,2017,21(6):978-982.
嵌合抗原受体T细胞免疫疗法治疗多发性骨髓瘤的研究进展
The review of application and challenge of CAR-T in the treatment of multiple myelomaLIU Yichen1,SUN Zhiqiang2,3,ZHEN Fang2,4 (1.Graduate School,Guizhou Medical University,Guiyang,Guizhou 550000,China;2.Department of Hematology, The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou 550000,China;3.Department of Hematology, Shenzhen Hospital Affiliated to Southern Medical University,Shenzhen,Guangdong 518000,China;4.Department of Hematology,Baiyun Hospital Affiliated to Guizhou Medical University,Guiyang,Guizhou 550000,China) Abstract:
投稿时间:2016-08-10  
DOI:
中文关键词: 嵌合抗原受体  多发性骨髓瘤  免疫治疗
英文关键词: 
基金项目:
作者单位
刘奕晨 贵州医科大学研究生院,贵州 贵阳 550000 
孙志强 贵州医科大学附属医院血液内科, 贵州 贵阳 550000
南方医科大学深圳医院血液内科,广东 深圳 518000 
郑方 贵州医科大学附属医院血液内科, 贵州 贵阳 550000
贵州医科大学附属白云医院血液内科,贵州 贵阳 550000 
摘要点击次数: 1440
全文下载次数: 300
中文摘要:
      免疫疗法在恶性肿瘤治疗中的应用正日益受到关注。嵌合抗原受体(CAR)技术是一种新兴的免疫疗法,在血液肿瘤的治疗上具有巨大的潜力。嵌合抗原受体T细胞免疫疗法(CAR-T)可通过特异性识别靶抗原来杀伤骨髓瘤细胞,使治疗复发难治性多发性骨髓瘤成为可能。该文重点对CAR-T在多发性骨髓瘤治疗方面的研究进展作一综述,并对可能作为CAR-T治疗多发性骨髓瘤的靶抗原进行了分析。
英文摘要:
      Application of immunotherapy in malignant tumor has widely been focused.Chimeric antigen receptor is one of the emerging immunotherapy and has enormous potentiality to treat hematologic neoplasms.Chimeric antigen receptor-modified Tcells(CAR-T) may contribute to treat multiple myeloma as CAR-T can kill target myeloma cells by means of identifying the target antigen.In this article,the research advances of CAR-T in treating multiple myeloma were reviewed,and the antigens which may be an effective target for CAR-T in eliminating myeloma cells were analyzed.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮